A Double-blind, Randomized, Active-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis
Latest Information Update: 16 Jul 2020
At a glance
- Drugs Tegoprazan (Primary) ; Esomeprazole
- Indications Erosive oesophagitis
- Focus Therapeutic Use
- Sponsors CJ HealthCare; HK inno.N
Most Recent Events
- 14 Dec 2016 Status changed from recruiting to completed.
- 03 Jun 2015 New trial record